Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

42.39 +0.71 (+1.70%)
Streaming Delayed Price Updated: 12:32 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Xenon Pharmaceuticals: Q2 Earnings Insights
  Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency
Via Benzinga
Xenon Pharmaceuticals Shares Drop On Proposed Public Offering
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
  Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Xenon Pharmaceuticals Q1 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Why Xenon Pharma Flirted With A Breakout — And Then Sacrificed It All
The company had bullish results in seizure treatment. But it wasn't enough. 
Via Investor's Business Daily
US Stock Futures Mixed Ahead Of Jobless Claims, Powell Testimony
Pre-open movers 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Looking Into Xenon Pharmaceuticals's Return On Capital Employed
According to Benzinga Pro data, during Q1, Xenon Pharmaceuticals (NASDAQ:XENE) posted sales of $8.77 million. Earnings were up 23.06%, but Xenon Pharmaceuticals still reported an overall loss of $19.67... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
Swing Trading Stock Watchlist For April 11 And Beyond
The stock market's health is neutral. It is not bad, but it is not great either. I’m willing to take long trades in the stocks discussed if they form valid trade setups and trigger, but I’m not being... 
Via Talk Markets
Swing Trading Stock Watchlist For April 4 And Beyond
The stock market's health has improved. That means I have the green light to buy stocks that are forming quality trade setups. Let's dive into what I have been looking at this week. 
Via Talk Markets
Xenon Pharmaceuticals's Return On Capital Employed Overview
Xenon Pharmaceuticals (NASDAQ:XENE) brought in sales totaling $3.74 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 65.52%, resulting in... 
Via Benzinga
Recap: Xenon Pharmaceuticals Q4 Earnings
Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Xenon Pharmaceuticals's Earnings: A Preview
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement.... 
Via Benzinga
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory... 
Via Benzinga
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chi... 
Via Benzinga
Xenon Pharmaceuticals Scores As Epilepsy Results Highlight 'Competitive Profile'
More than half of high-dose patients reported a 50% decline in monthly seizures. 
Via Investor's Business Daily
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal... 
Via Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
Exposures COVID-19 Product Safety
Xenon Pharmaceuticals Has a Great Story But Too High a Price
XENE stock is a valuable stock market lesson about separating great expectations for stocks from the company's true fundamentals. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2021
Upgrades For Boot Barn Holdings Inc (NYSE: 
Via Benzinga
Xenon: Heading Toward Phase III With Strong Momentum
XENE stock is on solid footing after strong trial results 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.